// App-Quantinova.ai

LBA40_PR : ARIEL3: A phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC)

Researchers

Presenter

  • J.Ledermann

Principal Investigators

  • D.Lorusso

  • C.Aghajanian

  • A.Oaknin

  • A.Dean

  • N.Colombo

  • J.Weberpals

  • A.Clamp

  • G.Scambia

  • A.Leary

  • R.Holloway

  • D.M.O'Malley

  • T.Cameron

  • L.Maloney

  • S.Goble

  • K.K.Lin

  • J.Sun

  • H.Giordano

  • R.Coleman

Medical Centers

  • Gynaecological Oncology, University College London Cancer Institute and UCL Hospitals, London, UK

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • MITO and Unita di Ginecologia Oncologica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, New York

  • Medical Oncology Department, Breast Cancer Group, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Department of Oncology, St John of God Subiaco Hospital, Subiaco, Australia

  • Gynecologic Cancer Program, European Institute of Oncology and University of Milan-Bicocca, Milan, Italy

  • Division of Neurology, Ottawa Hospital Research Institute, Ottawa, ON, Canada

  • Medical Oncology, The Christie NHS Foundation Trust and University of Manchester, Manchester, UK

  • Gynecologic Oncology, Università Cattolica Roma, Rome, Italy

  • Gustave Roussy Cancer Center, INSERM U981, and Groupe D'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Villejuif, France

  • Department of Hematology/Oncology, Florida Hospital Cancer Institute, Orlando, FL, USA

  • Clinical Research Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH, USA

  • Clinical Science, Clovis Oncology, Inc., Boulder, CO, USA

  • Biostatistics, Clovis Oncology, Inc., Boulder, CO, USA

  • Cancer Genomics, Clovis Oncology, Inc., Boulder, CO, USA

  • Biomarker Development and Analysis, Foundation Medicine, Cambridge, MA, USA

  • Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Locations

  • United Kingdom

  • Canada

  • Italy

  • United States

  • Spain

  • Australia

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Cancer antigen 125

  • BRCA mutation

Drug/Treatment

  • Rucaparib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved